Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICAL PC: Cardiovascular and Lifestyle Risk Factor Modification in Prostate Cancer
NCT03127631Active, not recruiting
- Sponsor
- McMaster University
- Start
- Oct 2015
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Randomised, open-label trial of ulinastatin in cardiovascular disease (CVD) (2 arms), sponsored by McMaster University. Primary endpoints: Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control and systolic blood pressure control and Time to the first occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure. Started Oct 2015; status: active, not recruiting.
02
Drugs
ulinastatin
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03127631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127631.